Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients
López, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Depreux Niño, Nathalie (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Bielsa, Isabel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Roger, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Quirant-Sanchez, Bibiana (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Basagaña, Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Jurgens, Yanina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Padró-Casas, Clara (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Miquel, Sira (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Martínez Cáceres, Eva María (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Teniente Serra, Aina (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)

Date:	2024
Abstract:	Background: Chronic spontaneous urticaria (CSU) is a highly prevalent and difficult to manage cutaneous disease characterized by the presence of recurrent urticaria, angioedema, or both, for a period of 6 weeks or longer. One of the biological treatments used for patients with CSU with an autoimmune background and bad control of the disease is omalizumab, an anti-IgE monoclonal antibody. The understanding of the mechanism of action of this biological drug in CSU along with the identification of potential biomarkers of clinical response can be helpful in the personalized management of the disease. Objective: The purpose of this study was to analyze the effect of omalizumab on peripheral blood lymphocyte subpopulations in patients with CSU in order to identify potential biomarkers of treatment response. Methods: We analyzed 71 patients with CSU [33 under omalizumab and 38 under non-immunomodulatory drugs (treated with antihistamines; NID)] and 50 healthy controls. An exhaustive immunophenotyping of whole blood T-cell subpopulations, including naïve, central memory, effector memory, effector cells, Th1, Th2, and Th17 was performed by multiparametric flow cytometry. Moreover, in CSU patients, we analyzed markers of inflammation (ESR, DD, CRP), atopy (prick test, IgE quantification), and autoimmunity (anti-thyroid antibodies and indirect basophil activation test). To evaluate the clinical activity, the Urticaria Activity Score 7 (UAS 7) test was used. Results: In patients with CSU under treatment with omalizumab, there was a significant decrease in the percentage of naïve and an increase in the percentage of central memory CD4 T cells as well as a decrease in the percentage of naïve and increase in the percentage of effector CD8 T-cell subsets. Moreover, patients under treatment with omalizumab had higher percentages of Th1 and Th2 cells than patients under treatment with NID. Conclusion: The immune monitoring of T-cell subpopulations in patients with CSU starting omalizumab, may be a useful strategy to analyze treatment response in the clinical practice.
Grants:	Agència de Gestió d'Ajuts Universitaris i de Recerca 2021/SGR-00002
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Chronic urticaria ; Autoimmune chronic urticaria ; Immune profile ; Omalizumab ; Immune system
Published in:	Frontiers in immunology, Vol. 15 (August 2024) , ISSN 1664-3224

DOI: 10.3389/fimmu.2024.1413233
PMID: 39229257

10 p, 3.2 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles